Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT02660580 is registered in ClinicalTrials.gov with Fresenius Kabi SwissBioSim GmbH as lead sponsor.

NCT NCT02660580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02660580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Phase
Phase 3
Overall status
Completed
Start date
February 16, 2016
Completion date
December 18, 2017
Enrollment
443 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe plaque psoriasis, plaque type psoriasis, psoriasis